Lignin is a nontoxic and biocompatible biopolymer with many promising characteristics, including a high tensile strength and antioxidant properties. This natural polymer can be processed through several chemical methods and modified into lignin nanomaterials for potential biomedical applications. This review summarizes the latest developments in nanolignin (NL)-based biomaterials for cancer therapy; various NL applications related to cancer therapy are considered, including drug and gene delivery, biosensing, bioimaging, and tissue engineering. The manuscript also outlines the potential use of these materials to improve the therapeutic potency of chemotherapeutic drugs by decreasing their dose and reducing their adverse effects. Due to its high surface area-to-volume ratio and the easy modification of its chemical components, NL could serve as an appropriate matrix for the binding and controlled release of various pharmaceutical agents. Moreover, the challenges in the utilization of NL-based materials for cancer therapy are discussed, along with the prospects of advances in such nanomaterials for medical research applications.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/adhm.202300024 | DOI Listing |
Clin Lung Cancer
December 2024
Department of Radiation Oncology, University of California Davis Comprehensive Cancer Center, Sacramento, CA. Electronic address:
Sci Bull (Beijing)
January 2025
Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China. Electronic address:
Clin Breast Cancer
December 2024
Department of Oncology, Princess Margaret Hospital, Kowloon West Cluster, Hospital Authority, Hong Kong S.A.R., China. Electronic address:
Urol Oncol
January 2025
Vita-Salute San Raffaele University and IRCCS San Raffaele Hospital, Milan, Italy; Department of Medical Oncology, IRCCS San Raffaele University, Milan, Italy.
Treatment options for recurrent high-risk non-muscle-invasive bladder cancer (HR NMIBC) and muscle-invasive bladder cancer (MIBC) are limited, highlighting a need for clinically effective, accessible, and better-tolerated alternatives. In this review we examine the clinical development program of TAR-200, a novel targeted releasing system designed to provide sustained intravesical delivery of gemcitabine to address the needs of patients with NMIBC and of those with MIBC. We describe the concept and design of TAR-200 and the clinical development of this gemcitabine intravesical system in the SunRISe portfolio of studies.
View Article and Find Full Text PDFMed Clin (Barc)
January 2025
Servicio de Endocrinología y Nutrición, Hospital Regional Universitario de Málaga, Málaga, España.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!